Integrative Analysis of Epigenetic Modulation in Melanoma Cell Response to Decitabine: Clinical Implications
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Decitabine, an epigenetic modifier that reactivates genes otherwise suppressed by DNA promoter methylation, is effective for some, but not all cancer patients, especially those with solid tumors. It is commonly recognized that to overcome resistance and improve outcome, treatment should be guided by tumor biology, which includes genotype, epigenotype, and gene expression profile. We therefore took an integrative approach to better understand melanoma cell response to clinically relevant dose of decitabine and identify complementary targets for combined therapy. We employed eight different melanoma cell strains, determined their growth, apoptotic and DNA damage responses to increasing doses of decitabine, and chose a low, clinically relevant drug dose to perform whole-genome differential gene expression, bioinformatic analysis, and protein validation studies. The data ruled out the DNA damage response, demonstrated the involvement of p21(Cip1) in a p53-independent manner, identified the TGFbeta pathway genes CLU and TGFBI as markers of sensitivity to decitabine and revealed an effect on histone modification as part of decitabine-induced gene expression. Mutation analysis and knockdown by siRNA implicated activated beta-catenin/MITF, but not BRAF, NRAS or PTEN mutations as a source for resistance. The importance of protein stability predicted from the results was validated by the synergistic effect of Bortezomib, a proteasome inhibitor, in enhancing the growth arrest of decitabine in otherwise resistant melanoma cells. Our integrative analysis show that improved therapy can be achieved by comprehensive analysis of cancer cells, identified biomarkers for patient's selection and monitoring response, as well as targets for improved combination therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Polycomb group protein EZH2 directly controls DNA methylation
Viré, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., Van Eynde, A., Bernard, D., Vanderwinden, J.-M., et al. (2006) · Nature · doi:10.1038/nature04431 · Cited by 2,204
Phenotypic plasticity and the epigenetics of human disease
Feinberg, A. P. (2007) · Nature · doi:10.1038/nature05919 · Cited by 1,613 · cited 1×
“Aberrant DNA methylation is the cause for downregulation of tumor suppressors, apoptotic factors, DNA repair enzymes, adhesion molecules and immunomodulators involved in malignant progression of various cancers [9,11,12].”
BackgroundMITF: master regulator of melanocyte development and melanoma oncogene
Levy, C., Khaled, M., & Fisher, D. E. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.07.008 · Cited by 1,169 · cited 2×
“The extent of target gene knockdown (b-catenin), as well as downstream targets, MITF, Myc (b-catenin target genes), BCL2 (MITF target gene) [45], were assessed at protein levels by successive Western blotting with antibodies to b-catenin as a control.”
Background
Cited by
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
Krauthammer, M., Kong, Y., Ha, B. H., Evans, P., Bacchiocchi, A., McCusker, J. P., Cheng, E., Davis, M. J., Goh, G., Choi, M., et al. (2012) · Nature Genetics · doi:10.1038/ng.2359 · Cited by 1,191
Self-citationKarreth, F. A., Tay, Y., Perna, D., Ala, U., Tan, S. M., Rust, A. G., DeNicola, G., Webster, K. A., Weiss, D., Perez-Mancera, P. A., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.032 · Cited by 653
Self-citationHalaban, R., Zhang, W., Bacchiocchi, A., Cheng, E., Parisi, F., Ariyan, S., Krauthammer, M., McCusker, J. P., Kluger, Y., & Sznol, M. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00685.x · Cited by 326
Self-citationGenome-wide screen of promoter methylation identifies novel markers in melanoma
Koga, Y., Pelizzola, M., Cheng, E., Krauthammer, M., Sznol, M., Ariyan, S., Narayan, D., Molinaro, A. M., Halaban, R., & Weissman, S. M. (2009) · Genome Research · doi:10.1101/gr.091447.109 · Cited by 194
“All cell strains carried the BRAF activating mutation, none harbored the NRAS codon 61 mutation, four carried PTEN loss of heterozygosity (LOH), one a known PTEN variant (Pro38Ser), while one carried inactivating CTNNB1 mutation (Ser33Cys) (Halaban et al. 2009).”
BackgroundSelf-citationGiuliano, S., Cheli, Y., Ohanna, M., Bonet, C., Beuret, L., Bille, K., Loubat, A., Hofman, V., Hofman, P., Ponzio, G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2913 · Cited by 135
Metadata
- Authors
- Halaban, R., Krauthammer, M., Pelizzola, M., Cheng, E., Kovacs, D., Sznol, M., Ariyan, S., Narayan, D., Bacchiocchi, A., Molinaro, A., Kluger, Y., Deng, M., Tran, N., Zhang, W., Picardo, M., & Enghild, J. J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-02-23
- Volume
- 4
- Issue
- 2
- Pages
- e4563
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2010076338
- Cited by
- 58
- References
- 3
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Integrative Analysis of Epigenetic Modulation in Melanoma Cell Response to Decitabine: Clinical Implications. https://app.cochat.ai/papers/10.1371/journal.pone.0004563
- The paper
- Halaban, R., Krauthammer, M., Pelizzola, M., Cheng, E., Kovacs, D., Sznol, M., Ariyan, S., Narayan, D., Bacchiocchi, A., Molinaro, A., Kluger, Y., Deng, M., Tran, N., Zhang, W., Picardo, M., & Enghild, J. J. (2009). Integrative Analysis of Epigenetic Modulation in Melanoma Cell Response to Decitabine: Clinical Implications. PLoS ONE. https://doi.org/10.1371/journal.pone.0004563
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.